A Novel Self-Assembly Nanocrystal as Lymph Node-Targeting Delivery System: Higher Activity of Lymph Node Targeting and Longer Efficacy Against Lymphatic Metastasis

2019 ◽  
Vol 20 (7) ◽  
Author(s):  
Yuling Mao ◽  
Jun Liu ◽  
Tianyu Shi ◽  
Ge Chen ◽  
Shujun Wang
Keyword(s):  
Lymph Node ◽  
Delivery System ◽  
Lymphatic Metastasis ◽  
Self Assembly ◽  
Targeting Delivery ◽  
Lymph Node Targeting

Lymph Node — Targeting Delivery of Adriamycin by Liposomal Administration into Gastric Submucosa in Rabbits

1993 ◽  
pp. 360-362
Author(s):  
Yoshimi Akamo ◽  
Isamu Mizuno ◽  
Toshihisa Yotsuyanagi ◽  
Tatsuo Ichino ◽  
Noritaka Tanimoto ◽  
...  
Keyword(s):  
Lymph Node ◽  
Targeting Delivery ◽  
Lymph Node Targeting

scholarly journals Immunopotentiation by Lymph-Node Targeting of a Malaria Transmission-Blocking Nanovaccine

2021 ◽  
Vol 12 ◽  
Author(s):  
Gregory P. Howard ◽  
Nicole G. Bender ◽  
Prachi Khare ◽  
Borja López-Gutiérrez ◽  
Vincent Nyasembe ◽  
...  
Keyword(s):  
Lymph Node ◽  
Malaria Transmission ◽  
Delivery System ◽  
Specific Antibody ◽  
High Antibody ◽  
Transmission Blocking ◽  
Mosquito Midgut ◽  
Cpg Oligodeoxynucleotide ◽  
Biodegradable Nanoparticle ◽  
Lymph Node Targeting

A successful malaria transmission blocking vaccine (TBV) requires the induction of a high antibody titer that leads to abrogation of parasite traversal of the mosquito midgut following ingestion of an infectious bloodmeal, thereby blocking the cascade of secondary human infections. Previously, we developed an optimized construct UF6b that elicits an antigen-specific antibody response to a neutralizing epitope of Anopheline alanyl aminopeptidase N (AnAPN1), an evolutionarily conserved pan-malaria mosquito midgut-based TBV target, as well as established a size-controlled lymph node targeting biodegradable nanoparticle delivery system that leads to efficient and durable antigen-specific antibody responses using the model antigen ovalbumin. Herein, we demonstrate that co-delivery of UF6b with the adjuvant CpG oligodeoxynucleotide immunostimulatory sequence (ODN ISS) 1018 using this biodegradable nanoparticle vaccine delivery system generates an AnAPN1-specific immune response that blocks parasite transmission in a standard membrane feeding assay. Importantly, this platform allows for antigen dose-sparing, wherein lower antigen payloads elicit higher-quality antibodies, therefore less antigen-specific IgG is needed for potent transmission-reducing activity. By targeting lymph nodes directly, the resulting immunopotentiation of AnAPN1 suggests that the de facto assumption that high antibody titers are needed for a TBV to be successful needs to be re-examined. This nanovaccine formulation is stable at -20°C storage for at least 3 months, an important consideration for vaccine transport and distribution in regions with poor healthcare infrastructure. Together, these data support further development of this nanovaccine platform for malaria TBVs.

scholarly journals Lymph Node-Targeting Nanovaccine through Antigen-CpG Self-Assembly Potentiates Cytotoxic T Cell Activation

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Xiaobo Xi ◽  
Lijun Zhang ◽  
Guihong Lu ◽  
Xiaoyong Gao ◽  
Wei Wei ◽  
...  
Keyword(s):  
Immune Response ◽  
T Cells ◽  
Lymph Node ◽  
T Cell ◽  
Lymph Nodes ◽  
Self Assembly ◽  
Cytotoxic T Cell ◽  
Therapeutic Vaccines ◽  
Loading Efficiency ◽  
Lymph Node Targeting

Therapeutic vaccines that arouse the cytotoxic T cell immune response to reject infected cells have been investigated extensively for treating disease. Due to the large amounts of resident antigen-presenting cells (APCs) and T cells in lymph nodes, great efforts have been made to explore the strategy of targeting lymph nodes directly with nanovaccines to activate T cells. However, these nanovaccines still have several problems, such as a low loading efficiency and compromised activity of antigens and adjuvants derived from traditional complicated preparation. There are also safety concerns about materials synthesized without FDA approval. Herein, we construct an assembled nanoparticle composed of an antigen (ovalbumin, OVA) and adjuvant (CpG) to ensure its safety and high loading efficiency. The activity of both components was well preserved due to the mild self-assembly process. The small size, narrow distribution, negative charge, and good stability of the nanoparticle endow these nanovaccines with superior capacity for lymph node targeting. Correspondingly, the accumulation at lymph nodes can be improved by 10-fold. Subsequently, due to the sufficient APC internalization and maturation in lymph nodes, ~60% of T cells are stimulated to proliferate and over 70% of target cells are specifically killed. Based on the effective and quick cellular immune response, the assembled nanoparticles exhibit great potential as therapeutic vaccines.

scholarly journals Overcoming physiological barriers by nanoparticles for intravenous drug delivery to the lymph nodes

2021 ◽  
pp. 153537022110107
Author(s):  
Noah Trac ◽  
Eun Ji Chung
Keyword(s):  
Drug Delivery ◽  
Lymph Node ◽  
Lymph Nodes ◽  
Cancer Metastasis ◽  
Subcutaneous Administration ◽  
Mononuclear Phagocyte ◽  
Intravenous Drug ◽  
Rapid Clearance ◽  
Nanoparticle Design ◽  
Lymph Node Targeting

The lymph nodes are major sites of cancer metastasis and immune activity, and thus represent important clinical targets. Although not as well-studied compared to subcutaneous administration, intravenous drug delivery is advantageous for lymph node delivery as it is commonly practiced in the clinic and has the potential to deliver therapeutics systemically to all lymph nodes. However, rapid clearance by the mononuclear phagocyte system, tight junctions of the blood vascular endothelium, and the collagenous matrix of the interstitium can limit the efficiency of lymph node drug delivery, which has prompted research into the design of nanoparticle-based drug delivery systems. In this mini review, we describe the physiological and biological barriers to lymph node targeting, how they inform nanoparticle design, and discuss the future outlook of lymph node targeting.

Biocompatible, chimeric peptide-condensed supramolecular nanoparticles for tumor cell-specific siRNA delivery and gene silencing

2014 ◽  
Vol 50 (58) ◽  
pp. 7806-7809 ◽  
Author(s):  
Hangxiang Wang ◽  
Wei Chen ◽  
Haiyang Xie ◽  
Xuyong Wei ◽  
Shengyong Yin ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Gene Silencing ◽  
Delivery System ◽  
Self Assembly ◽  
Sirna Delivery ◽  
Single Step ◽  
Chimeric Peptide ◽  
Supramolecular Nanoparticles ◽  
Sirna Delivery System

A practical and tumor cell-specific siRNA delivery system was developedviasingle-step self-assembly of an arginine-rich chimeric peptide with siRNA.

Regulation of melanoma cell growth by a miR-21 loaded targeted delivery system based on microparticles and nanoparticles targeting phosphatase and tensin homolog (PTEN)

2021 ◽  
Vol 11 (11) ◽  
pp. 1766-1773
Author(s):  
Lei Jin ◽  
Tong Yang
Keyword(s):  
Delivery System ◽  
Self Assembly ◽  
Targeted Delivery ◽  
Melanoma Cells ◽  
Phosphatase And Tensin Homolog ◽  
Tensin Homolog ◽  
Assembly Method ◽  
New Strategy ◽  
Low Levels ◽  
Phosphatase And Tensin Homologue

The modulatory effect of miR-21 on the proliferation of melanoma cells through stimulation of PTEN (Phosphatase and tensin homologue deleted on chromosome 10) expression was investigated in the current study. PTEN, as a tumor suppressor, is expressed in low levels in melanoma tissues and cell lines. Nevertheless, miR-21 can stimulate cancer development and suppress cell apoptosis. Overexpression of PTEN substantially impaired the proliferation of miR-21-treated melanoma cells. In addition, miR-21 and PTEN were observed to exhibit a combinatorial effect, whereas miR-21 could negatively regulate the expression of PTEN. In conclusion, these findings demonstrate that miR-21 affects melanoma development by targeting PTEN, establishing a new strategy for treating malignant melanoma. Furthermore, in this study, microparticles and nanoparticles were employed as carriers to construct, through the self-assembly method, nanocapsules carrying miR-21 in order to develop an efficient nanocapsule delivery system of miR-21 against melanoma cells.

Corrigendum to “Designing an immunocyte-targeting delivery system by use of beta-glucan” [Vaccine 36 (2018) 186–189]

Vaccine ◽  
2018 ◽  
Vol 36 (45) ◽  
pp. 6892
Author(s):  
Noriko Miyamoto ◽  
Shinichi Mochizuki ◽  
Kouji Kobiyama ◽  
Ken J. Ishii ◽  
Kazuo Sakurai
Keyword(s):  
Delivery System ◽  
Beta Glucan ◽  
Targeting Delivery

scholarly journals Identification of lymph node metastasis-related microRNAs in lung adenocarcinoma and analysis of the underlying mechanisms using a bioinformatics approach

2016 ◽  
Vol 242 (7) ◽  
pp. 709-717 ◽  
Author(s):  
Li Yan ◽  
Demin Jiao ◽  
Huizhen Hu ◽  
Jian Wang ◽  
Xiali Tang ◽  
...  
Keyword(s):  
Transcription Factors ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Lung Adenocarcinoma ◽  
Lymphatic Metastasis ◽  
Target Genes ◽  
Bioinformatics Analyses ◽  
Node Metastasis ◽  
Primary Lung Adenocarcinoma ◽  
Underlying Mechanisms

This study aimed to screen lymphatic metastasis-related microRNAs (miRNAs) in lung adenocarcinoma and explore their underlying mechanisms using bioinformatics. The miRNA expression in primary lung adenocarcinoma, matched adjacent non-tumorigenic and lymph node metastasis tissues of patients were profiled via microarray. The screened metastasis-related miRNAs were then validated using quantitative real-time PCR in a second cohort of lung adenocarcinoma patients with lymphatic metastasis. Significance was determined using a paired t-test. Target genes of the metastasis-related miRNAs were predicted using TargetScan, and transcription factors (TFs) were predicted based on the TRANSFAC and ENCODE databases. Furthermore, the related long non-coding RNAs (lncRNAs) were screened with starBase v2.0. The miRNA-TF-mRNA and lncRNA-miRNA-mRNA networks were constructed to determine the key interactions associated with lung adenocarcinoma metastasis. According to the miRNA microarray results, there were 10 miRNAs that were differentially expressed in metastatic tissues compared with primary tumor and adjacent non-tumorigenic tissues. Among them were increased levels of miR-146a-5p, miR-342-3p, and miR-150-5p, which were validated in the second cohort. Based on the miRNA-TF-mRNA network, vascular endothelial growth factor A and transcription factors (TFs) including TP53, SMAD4, and EP300 were recognized as critical targets of the three miRNAs. Interactions involving SNHG16–miR-146a-5p–SMAD4 and RP6-24A23.7–miR-342-3p/miR-150-5p–EP300 were highlighted according to the lncRNA-miRNA-mRNA network. miR-146a-5p, miR-342-3p, and miR-150-5p are lymphatic metastasis-related miRNAs in lung adenocarcinoma. Bioinformatics analyses demonstrated that SNHG16 might inhibit the interaction between miR-146a-5p and SMAD4, while RP6-24A23.7 might weaken miR-342-3p–EP300 and miR-150-5p–EP300 interactions in metastasis.

Sign in / Sign up

Export Citation Format

Share Document